Bionano Genomics, Inc.BNGOEarnings & Financial Report
Bionano Genomics develops and commercializes proprietary optical genome mapping technology and diagnostic solutions. Its products detect large structural genomic variants with high precision, serving global research institutions, biopharma firms, and clinical labs for oncology, rare disease, and reproductive health use cases.
BNGO Q4 FY2025 Key Financial Metrics
Revenue
$8.0M
Gross Profit
$3.4M
Operating Profit
$-8.5M
Net Profit
$-7.9M
Gross Margin
42.8%
Operating Margin
-107.4%
Net Margin
-99.8%
YoY Growth
-2.6%
EPS
$-0.12
Bionano Genomics, Inc. Q4 FY2025 Financial Summary
Bionano Genomics, Inc. reported revenue of $8.0M (down 2.6% YoY) for Q4 FY2025, with a net profit of $-7.9M (up 60.6% YoY) (-99.8% margin). Cost of goods sold was $4.6M, operating expenses totaled $11.9M.
Key Financial Metrics
| Total Revenue | $8.0M |
|---|---|
| Net Profit | $-7.9M |
| Gross Margin | 42.8% |
| Operating Margin | -107.4% |
| Report Period | Q4 FY2025 |
Bionano Genomics, Inc. Annual Revenue by Year
Bionano Genomics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $28.5M).
Bionano Genomics, Inc. Quarterly Revenue & Net Profit History
Bionano Genomics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $8.0M | -2.6% | $-7.9M | -99.8% |
| Q3 FY2025 | $7.4M | +21.3% | $-8.5M | -115.4% |
| Q2 FY2025 | $6.7M | -13.4% | $-6.9M | -101.8% |
| Q1 FY2025 | $6.5M | -26.4% | $-3.1M | -48.0% |
| Q4 FY2024 | $8.2M | -23.9% | $-20.1M | -246.5% |
| Q3 FY2024 | $6.1M | -34.8% | $-44.2M | -728.6% |
| Q2 FY2024 | $7.8M | -10.3% | $-16.2M | -208.8% |
| Q1 FY2024 | $8.8M | +18.3% | $-31.4M | -358.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.8M | $7.8M | $6.1M | $8.2M | $6.5M | $6.7M | $7.4M | $8.0M |
| YoY Growth | 18.3% | -10.3% | -34.8% | -23.9% | -26.4% | -13.4% | 21.3% | -2.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $158.0M | $129.4M | $87.4M | $76.7M | $78.4M | $76.0M | $79.1M | $73.6M |
| Liabilities | $75.2M | $49.0M | $38.5M | $41.3M | $30.2M | $30.6M | $29.3M | $29.2M |
| Equity | $82.8M | $80.3M | $48.9M | $35.4M | $48.2M | $45.4M | $49.8M | $44.4M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-28.1M | $-21.0M | $-13.3M | $-6.5M | $-2.8M | $-3.5M | $-5.9M | $-4.2M |